Evercore ISI has increased its price target for BioMarin Pharmaceutical Inc., citing a valuation gap as the primary reason for the adjustment. The firm believes that the current market price does not accurately reflect the company's potential value. This revision may influence investor perceptions and trading activity related to BioMarin's stock in the coming days. The updated target reflects Evercore ISI's analysis of the company's financial performance and market position.
Related Articles
Don't miss out on breaking stories and in-depth articles.